Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business)

Cell and gene therapy contract development and manufacturing (viral vector CDMO platform)

30K US cases/yr · $4.5B Global viral vector CDMO market 2021 (USD MM) · 1500 Active cell and gene therapy clinical programs globally 2021

Disease Overview

This is a CDMO/manufacturing capability acquisition rather than a disease-specific deal — Henogen S.A. (the Novasep viral vector manufacturing business in Seneffe, Belgium) provides AAV (adeno-associated virus), lentiviral and adenoviral vector manufacturing capacity for cell and gene therapy developers globally. The end-market disease scope spans the entire approved and clinical-stage gene therapy universe. At deal date (April 2021) FDA-approved gene therapies included Luxturna (voretigene neparvovec, RPE65-mediated retinal dystrophy, Spark/Roche, 2017), Zolgensma (onasemnogene abeparvovec, spinal muscular atrophy, Novartis/AveXis, 2019), Imlygic (talimogene laherparepvec, melanoma, Amgen, 2015), Yescarta/Tecartus/Kymriah/Breyanzi/Abecma autologous CAR-Ts and Strimvelis (ADA-SCID, GSK/Orchard). The pipeline included hundreds of preclinical-to-Phase 3 programs spanning hemophilia A/B (Roche/Spark, BioMarin Roctavian, CSL Hemgenix), Duchenne muscular dystrophy (Sarepta SRP-9001/Elevidys), sickle cell disease and beta-thalassemia (bluebird Zynteglo/Lyfgenia, Vertex/CRISPR Casgevy), and broader rare disease scope including LSDs, Stargardt, X-linked retinoschisis. Manufacturing constraint — particularly AAV viral vector capacity — was widely identified as the rate-limiting step for the gene therapy industry, with multi-year wait times for slot allocation at major CDMOs in 2020-2022.

Competitive Landscape

At deal date the viral vector CDMO landscape was dominated by a handful of large platforms competing on capacity, regulatory experience and end-to-end services. Direct competitors to Thermo Fisher's Henogen acquisition included: Catalent's expanded gene therapy footprint via Paragon Bioservices ($1.2B, May 2019) plus MaSTherCell ($315M, Mar 2020), Lonza Pharma & Biotech (Houston AAV facility, Geleen lentivirus, Visp gene therapy expansion announced 2020-2021), Charles River Laboratories' Cognate BioServices ($875M, Apr 2021 — same week as Henogen) plus Vigene Biosciences ($292.5M, Aug 2021), Resilience (formerly National Resilience, $800M raise 2020-2021 building Seattle/Boston facilities), Oxford Biomedica (lentiviral specialist, Novartis Kymriah supply), WuXi Advanced Therapies (Philadelphia and Shanghai), and Fujifilm Diosynth Biotechnologies. Adjacent competition for end-customer wallet share included Pall, Cytiva (formerly GE Healthcare Life Sciences) and Sartorius bioprocessing equipment platforms. Thermo Fisher's existing CDMO footprint included Brammer Bio (gene therapy, $1.7B Mar 2019), Patheon ($7.2B Aug 2017), and integration of pharma services with its Life Sciences Solutions equipment business — Henogen adds European AAV/lentiviral capacity (Seneffe, Belgium) to complement US footprint. The viral vector CDMO market was forecast at ~$2-3B in 2021 growing to $7-10B by 2026 per Frost & Sullivan, driven by AAV gene therapy launches and broader CAR-T scale-up.